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Background. Once the diagnosis of Helicobacter pylori is confirmed,
treatment requires at least two antibiotics and an acid inhibitor for a
minimum of seven days. Unfortunately, treatment failures are being
frequently reported. Treatment regimens that include sequential
administration of antibiotics with acid inhibitors have been developed to
try and increase the rate of eradication.
Objective. To determine the effectiveness of a novel 10day sequential
therapy compared with the standard 10day triple therapy for treatment
of H. pylori infection in children.
Methods. A doubleblinded, randomised, controlled trial was conducted.
Children under the age of 16 years with recurrent abdominal pain
associated with dyspepsia and diagnosed with H. pylori by histology were
randomly allocated either to a 10day sequential treatment regimen or to
a 10day conventional triple therapy. Analysis of the outcome of this
study was based on clinical improvement and confirmed H. pylori
eradication based on stool H. pylori antigen detection and/or repeat
endoscopy.
Results. Of the 71 patients included in the analysis, 45 (63.4%) were
given the 10day conventional treatment while 26 (36.6%) received the
10day sequential treatment. There was no difference in clinical
improvement after treatment in the two therapies. However, there was a
significant difference in the eradication of H. pylori between the
conventional v. sequential regimens (48.8% v. 84.6%, respectively;
p=0.02, odds ratio 0.19).
Conclusion. The sequential treatment had a significantly higher H. pylori
eradication rate than the conventional treatment.
S Afr Med J 2013;103(12):921924. DOI:10.796/SAMJ.7012
Helicobacter pylori are Gramnegative, spiral, flagellate bacilli that cause
acute and chronic gastritis and peptic ulcer disease in both children and
adults. 1 H. pylori was first isolated in 1983 by Warren and Marshal.2 This
discovery was a major breakthrough in the management of dyspepsia.3
The organism has also been recognised as a class 1 gastric carcinogen
and infection at a younger age is thought to increase the risk of
developing gastric cancer.4 Children are infected with H. pylori at a much
younger age in developing countries, some of which report higher rates of
gastric cancer.5
The prevalence of H. pylori infection varies from 20% to 50% in
industrialised countries,6 while studies have shown that the prevalence is
high in regions of Africa and Asia. Therapy can be complicated by various

factors including drug costs and availability, treatment sideeffects, and
the presence of bacterial strains that are antibiotic resistant.7
Antibiotic resistance is an everincreasing problem in the treatment of
most microbial infections including H. pylori. The widespread and
sometimes indiscriminate use of antibiotics in developing countries has
resulted in a higher prevalence of resistance than in industrialised
countries.8 New antimicrobial agents are being developed to overcome
the problem of antibiotic resistance in bacterial pathogens, such as a
combination of antibiotics with plant extract and other natural products
that possess antimicrobial activity.9 The standard and most
recommended treatment for the eradication of H. pylori, in all
international guidelines, is triple therapy using a combination of two
antibiotics (clarithromycin plus amoxicillin or metronidazole) and a proton
pump inhibitor (PPI) for at least 7 days.10 However, a recent meta
analysis that included over 53 000 patients showed that the eradication
rate after a standard triple treatment is currently below 80%.11 Thus
eradication is not achieved in at least 1/5 patients, prompting research on
sequential therapy.
A novel 10day sequential treatment regimen comprising a PPI and
amoxicillin double therapy for 5 days followed by a PPI, clarithromycin and
tinidazole triple therapy for a further 5 days has been shown to achieve H.
pylori eradication rates of 95% and 97% in European adults and children,
respectively. This regimen, compared with the conventional triple therapy,
improved eradication rates by 18% and 22%, respectively, was well
tolerated, safe and had good compliance in both adults and children.12 ,
13
Local data on eradication rates are not available but anecdotal evidence
suggests that there are increasing failure rates to the standard triple
therapy regimens.

Objective
To establish whether there was any difference in the treatment of H. pylori
infection using the 10day sequential therapy v. the 10day conventional
triple therapy, based on clinical improvement of the patients and H. pylori
eradication.

Methods
Study design
A doubleblinded, randomised, controlled trial was conducted on children
under the age of 16 years.

Study setting and participants
The study was carried out at the Paediatric Gastroenterology Clinic, Aga
Khan University Hospital, Kenya between March 2007 and October 2007.
Children under the age of 16 years presenting with recurrent abdominal
pain (defined as abdominal pain present for at least three months)
associated with dyspepsia (pain or discomfort in the upper abdomen) and
diagnosed with H. pylori by histology were recruited from the clinic on a
consecutive basis. Children previously treated for H. pylori infection, those
who had taken any antibiotic, PPI or H2 receptor antagonist 4 weeks prior
to the study, and children with known allergies to antibiotics, were
excluded.
Permission for this study was granted by the Aga Khan University Hospital
Research and Ethics Committee. Informed consent was obtained from the
patients or caregivers prior to recruitment. All interviews were carried out
in private and all records were accessible only to the investigators.

Data collection

An upper endoscopy was done on all children with recurrent abdominal
pain and dyspepsia using the standard paediatric gastroscope under deep
sedation with propofol administered by an anaesthetist, and the
endoscopy findings were documented. Two biopsy specimens each from
gastric antrum and body were obtained and placed in 10% buffered
formalin for histopathology. All sections were Giemsa stained to detect
H. pylori. Inflammation, activity and other mucosal alterations such as
gland atrophy and intestinal metaplasia were evaluated semi
quantitatively, based on the Sidney system, by the study
histopathologist. Patients returned to the clinic a week after the
endoscopy examination. Those with a positive H. pylori test on histology
were recruited consecutively and a structured questionnaire was
administered to obtain detailed information on their clinical symptoms.
Participants were then referred to the pharmacy where an independent
pharmacist randomised patients to either the 10day sequential
treatment or the 10day conventional treatment. A computer programme
was used to generate random numbers to assign patients to either of the
two arms as they were recruited. Both the study physicians and the
patients were therefore blinded. A total of 104 patients were recruited
with 52 receiving sequential treatment while 52 were allocated to the
standard triple therapy arm (Fig. 1).
The 10day sequential therapy included 1 mg/kg/day omeprazole plus 50
mg/ kg/ day amoxicillin for 5 days followed by 1 mg/ kg/ day omeprazole
plus 15 mg/kg/day clarithromycin plus 20 mg/kg/day tinidazole for the
next 5 days. The 10day conventional triple therapy consisted of 1
mg/kg/day omeprazole plus 50 mg/kg/day amoxicillin plus 15 mg/kg/day
clarithromycin for 10 days.

Fig. 1. Study flow diagram.

Followup
The patients were asked to return at the end of the treatment period (two
weeks) so as to assess compliance and evaluate any adverse events. The
child’s parents/guardians were questioned regarding compliance with
medication schedules. There were no noncompliance issues. After six

weeks patients were seen as part of routine practice to assess possible
persistence of symptoms and to undergo a followup physical
examination. The outcome of the treatment was based on both clinical
improvement and whether H. pylori was eradicated. The eradication was
determined by use of a stool antigen test and/or a repeat histology
obtained at repeat endoscopy.

Statistical analysis
χ2 analysis was performed to assess differences in both treatment
regimes, with p<0.05 being considered significant. Frequencies for age
and sex of the participants were also analysed. Analysis was based on
both clinical improvement and H. pylori eradication.

Results
Equal numbers of patients were initially recruited in both arms of
treatment. Although the majority of patients in the sequential v.
conventional treatment groups (n=41;79% v. n=49;94%, respectively)
were seen at the sixweek followup visit, only 26 (63%) of those in the
sequential arm underwent confirmation of H. pylori eradication v. 45
(92%) in the conventional therapy arm.
A total of 71 children who were followed up to the six weeks were included
in this study. The male to female ratio was 1.15:1. The ages of these
children varied from 2 to 16 years with a mean age of 8.9 years (standard
deviation (SD) ±3.096). Final analysis was done on 45 patients (63.4%)
in the conventional treatment arm and 26 (36.6%) in the sequential
treatment arm (Table 1). There were more males than females (53.5%
and 46.5%, respectively) and just more than a third of the patients were
>8 years of age. In total, 45/71 (63.4%) patients received conventional
therapy while 26 (36.6%) were given sequential treatment.

After randomisation, the group that received the conventional therapy
had a mean age of 9.1 years (SD ±3.11; standard error (SE) ±0.46). The
sequential therapy group had a mean age of 8.81 years (SD ±3.12;
SE ±0.61). The other demographic factors analysed are shown in Table 2.
Although the gender ratio was similar in the two groups, there were more
children in the 8  11year and fewer children in the 12  16year age
categories in the sequential group v. the conventional group.

Clinical improvement was observed in 88.7% of patients after treatment,
while eight (11.3%) did not show improvement. Forty patients (88.9%) in
the conventional treatment arm showed clinical improvement v. 23
(88.5%) of those in the sequential treatment arm. There was no
significant difference in clinical improvement between the two regimens
(p=0.95; odds ratio (OR) 1.04). Neither gender (p=0.19) nor age
(p=0.79) of the participants was significantly associated with clinical
improvement (Table 3). Clinical improvement (resolution of dyspeptic
symptoms) was seen in almost 90% in both treatment groups. Neither
age nor sex differences were noted in the two groups.

Of the 71 patients, H. pylori was eradicated in 84.6% of the children who
had received the sequential treatment v. 48.8% of those on conventional
treatment, the difference being highly significant (p=0.02) (Table 4).
Sequential therapy resulted in significantly higher eradication of H. pylori
(84.6%) than conventional therapy (48.8%). Very few patients
consented to a repeat endoscopy.

Discussion
There is a general consensus that more effective firstline treatment
regimens for H. pylori are required to bring the eradication rate closer to
100%. Standard triple therapy falls well short of this target, even when it
is administered for 14 days.14
This study assessed both clinical improvement of the patient and H. pylori
eradication after treatment. There was no difference in clinical
improvement for both regimens, suggesting that resolution of symptoms
after treatment did not necessarily mean eradication of the organism.
Slightly more than a third of the patients were in the 4  7year age
category, suggesting early acquisition of H. pylori and early inflammatory
changes. This has been noted in studies from developing countries.2
With reference to H. pylori eradication, patients on the 10day sequential
therapy arm had a much higher H. pylori eradication rate than patients
who received conventional treatment (84.6% v. 48.8%, respectively).
There was a significant difference in eradication of H. pylori between the
two regimens (p=0.02). Previous studies have also shown that sequential
therapy achieves better eradication rates than 7day triple therapy. In a
study by Zullo et al.,12 eradication rates for the sequential therapy were
92% by intent to treat and 95% per protocol. A recent study from
Turkey15 found that the eradication rate was higher for sequential
therapy (93.7%) than standard therapy (46.4%). These findings are
similar to the findings in our study. However, the eradication rates with
sequential therapy in our study were still lower. This may be related to the
more prevalent misuse of antibiotics in developing countries resulting in
more resistant bacterial strains.16 The observed low eradication rates on
the standard therapy regimen in this study, prompts reevaluation of the
currently used firstline treatment for H. pylori infection in Kenya.
The superiority of sequential therapy over standard therapy may be
related to a reduction in bacterial load with the initial phase of treatment
with amoxicillin, which reduces the chances of developing mutations
causing metronidazole and clarithromycin resistance. 17 A notable finding
was resolution of abdominal symptoms in almost 90% of patients in both
treatment arms, despite a much lower eradication rate in the
conventional treatment group. This may be explained by the antacid
effect of the PPI causing symptomatic relief of dyspepsia. Unfortunately,
we could not follow the patients for long enough to ascertain if their
symptomatic relief was sustained. There were more patients in the 12 
16year age category in the sequential than the conventional group in the
final analysis. Whether this made a difference in the eradication rates is
difficult to predict, but it is expected that teenagers would be more likely
to complain if symptoms persisted.
This study is the first in Kenya to assess the effectiveness of the
sequential therapy in children in seeking to improve management of H.
pylori infections.

Study limitations
A major setback was that not all patients attended their sixweek review.
The study protocol also entailed a repeat endoscopy and/or stool H. pylori
antigen testing at this sixweek visit to assess eradication of H. pylori.
Unfortunately, a substantial number of parents would not agree to repeat
testing, especially endoscopy, as the children’s symptoms had improved.

After unblinding of the study, it was noted that most of those patients
who were lost to followup were patients from the sequential treatment
arm. Followup telephone calls to a few of the parents of these non
attendees confirmed that the patient was symptom free and that the
parent did not see the need for a repeat visit and/or endoscopy. It is
difficult to predict why more children in the sequential group did not
attend the review v. the conventional group. It is known that compliance
among patients who improve is poor compared with those who are still
unwell while cultural practices may also play a role.18 , 19 It is tempting
to suggest that because the children in the sequential group felt much
better than their counterparts in the conventional group, they failed to
come for their followup visit.
Based on findings from this study, there is a need to conduct a larger
randomised, controlled trial in various settings to fully confirm our
findings. However, we recommend that a sequential therapy regimen
should replace the standard triple therapy treatment for H. pylori infection
in children in Kenya.
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